quetiapine extended-release + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Personality Disorder
Conditions
Borderline Personality Disorder
Trial Timeline
Jun 1, 2008 → Mar 1, 2013
NCT ID
NCT00880919About quetiapine extended-release + Placebo
quetiapine extended-release + Placebo is a phase 3 stage product being developed by AstraZeneca for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00880919. Target conditions include Borderline Personality Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00880919 | Phase 3 | Completed |
Competing Products
12 competing products in Borderline Personality Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 77 |
| olanzapine | Eli Lilly | Pre-clinical | 23 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 52 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 77 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 51 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 32 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 49 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 36 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 44 |